CONGRESS|#EHA2021|Fredrik Schjesvold, further described tolerability of monoclonal antibodies
in elderly & pts with high risk disease. this treatment can maintain quality of life. #mmsm, #myeloma Oslo University hospital pic.twitter.com/U5SWCcQtbS
— Multiple Myeloma Hub (@MM_Hub) June 12, 2021